Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence

In patients undergoing percutaneous coronary intervention (PCI), the standard of care is dual antiplatelet therapy with a P2Y(12) inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin. Current clinical practice guidelines now recommend more potent P2Y(12) inhibitors (prasugrel or ticagrelor)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gower, Megan N, Ratner, Lindsay R, Williams, Alexis K, Rossi, Joseph S, Stouffer, George A, Lee, Craig R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419635/
https://www.ncbi.nlm.nih.gov/pubmed/32821149
http://dx.doi.org/10.2147/PGPM.S231475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419635/
https://www.ncbi.nlm.nih.gov/pubmed/32821149
http://dx.doi.org/10.2147/PGPM.S231475

Ejemplares similares